Con­gress' be­he­moth COM­PETES Act packs in pan­dem­ic pro­vi­sions for man­u­fac­tur­ers

As the fed­er­al gov­ern­ment writes more leg­is­la­tion to pre­pare for fu­ture pan­demics, drug man­u­fac­tur­ing con­ces­sions in the the Amer­i­ca COM­PETES Act passed last week the House of Rep­re­sen­ta­tives go a long way in do­ing just that.

The bill in­cludes com­po­nents to man­u­fac­tur­ing and sup­ply chain over­sight and was passed by a vote of 222-210 along par­ty lines. Be­cause of that vote, the bill’s po­ten­tial suc­cess in Con­gress is lim­it­ed. The bill is mas­sive — near­ly 3,000 pages — and in­cludes sim­i­lar pieces of leg­is­la­tion that were fea­tured in a ver­sion of the bill in Con­gress called the US In­no­va­tion and Com­pe­ti­tion Act, which was ad­vanced through the up­per cham­ber in June.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER